Global Statistics

All countries
179,815,172
Confirmed
Updated on June 22, 2021 10:03 pm
All countries
162,734,548
Recovered
Updated on June 22, 2021 10:03 pm
All countries
3,894,077
Deaths
Updated on June 22, 2021 10:03 pm

Global Statistics

All countries
179,815,172
Confirmed
Updated on June 22, 2021 10:03 pm
All countries
162,734,548
Recovered
Updated on June 22, 2021 10:03 pm
All countries
3,894,077
Deaths
Updated on June 22, 2021 10:03 pm

A Delhi hospital cures COVID-19 patients with antibody therapy, discharged within 12 hours

Digital Desk, New Delhi. Doctors at Sir Ganga Ram Hospital in New Delhi have successfully treated two patients suffering from COVID-19 using monoclonal antibody therapy. Both these patients were given Regeneron Pharmaceuticals’ antibody cocktail REGN-COV2 (casirivimab and imdevimab). Both the patients were discharged from the hospital within 12 hours of being given this therapy.

Dr Pooja Khosla, Senior Consultant, Department of Medicine, SGRH said that of the two patients who were given antibodies, one was a 36-year-old healthcare worker. The health worker was suffering from high-grade fever, cough, myalgia, weakness and

low blood cell count. The other patient was 80-year-old RK Razdan who was suffering from comorbidities like diabetes and hypertension. He was having high fever and cough. After 8 hours of monoclonal antibody therapy, the health of both patients improved significantly.

Monoclonal antibodies are identical copies of antibodies that target a specific antigen. This treatment has previously been used to treat deadly pathogens such as Ebola and HIV. REGCov2 has been developed by Regeneron Pharmaceutical which is conducting Phase-3 Covid-19 prevention trials. Dr Pooja Khosla said that monoclonal antibody therapy, if used at the right time, can help patients avoid hospitalization.

Antibodies are proteins that the body produces to protect against any disease. Monoclonal antibodies are made artificially in a laboratory. It is prepared according to the fight against any disease. Normal antibodies in any covid patient develop only after 14 days of infection. But the lab-made antibodies in this drug work immediately.

Cassirivimab and imdavimab are specifically designed to act against the spike protein of SARS-CoV-2, the virus causing the COVID pandemic. It blocks the attachment of the virus and its subsequent entry into human cells. Doses of 600–600 mg of both antibodies are given in this cocktail. It can be stored at 2-8°C temperature.

.



Source link

Leave a Reply

Hot Topics

Related Articles

You cannot copy content of this page
%d bloggers like this: